Q4 2025 · 13F-HR
GREAT POINT PARTNERS LLCholdings as filed
Filed 2026-02-17 · accession 0001172661-26-001093
$308.4M
Reported value
29
Positions
2025-12-31
Period end
The Brief · GREAT POINT PARTNERS LLC · Q4 2025
AI · grounded in 13F
GREAT POINT PARTNERS LLC established a new position in DISC MEDICINE INC valued at $19.85M. The fund also initiated new stakes in RAPT for $19.68M and VOR for $17.92M. On the sell side, the fund closed its position in ASNDUSD for a reduction of $14.91M and exited ABVX for $12.74M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $28.2M | 9.15% | 374,000 | Common | SHARED |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $21.1M | 6.85% | 1,750,000 | Common | SHARED |
| G9TY5A101 | ZURA | ZURA BIO LTD | $20.0M | 6.48% | 3,815,930 | Common | SHARED |
| 254604101 | IRON | DISC MEDICINE INC | $19.9M | 6.44% | 250,000 | Common | SHARED |
| 75382E208 | RAPT | RAPT THERAPEUTICS INC | $19.7M | 6.38% | 581,187 | Common | SHARED |
| 45258J102 | IMVT | IMMUNOVANT INC | $19.1M | 6.18% | 750,000 | Common | SHARED |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $18.5M | 6.00% | 400,000 | Common | SHARED |
| 929033207 | VOR | VOR BIOPHARMA INC | $17.9M | 5.81% | 1,370,107 | Common | SHARED |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $14.4M | 4.68% | 350,000 | Common | SHARED |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $12.4M | 4.03% | 806,273 | Common | SHARED |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $11.1M | 3.59% | 685,632 | Common | SHARED |
| 21217B100 | CTNM | CONTINEUM THERAPEUTICS INC | $9.1M | 2.96% | 800,000 | Common | SHARED |
| 29842P105 | EPRX | EUPRAXIA PHARMACEUTICALS INC | $9.1M | 2.94% | 1,200,000 | Common | SHARED |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $9.0M | 2.93% | 800,000 | Common | SHARED |
| 640268306 | NKTR | NEKTAR THERAPEUTICS | $8.9M | 2.89% | 210,732 | Common | SHARED |
| 91678A107 | UPB | UPSTREAM BIO INC | $8.1M | 2.64% | 300,000 | Common | SHARED |
| 64135M105 | NGNE | NEUROGENE INC | $7.2M | 2.34% | 350,000 | Common | SHARED |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $6.9M | 2.24% | 300,000 | Common | SHARED |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $6.9M | 2.23% | 4,683,711 | Common | SHARED |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $6.6M | 2.13% | 634,032 | Common | SHARED |
| 30054Y107 | EVMN | EVOMMUNE INC | $5.6M | 1.80% | 325,000 | Common | SHARED |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $5.6M | 1.80% | 183,330 | Common | SHARED |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $4.9M | 1.59% | 808,032 | Common | SHARED |
| 90466Y202 | UNCY | UNICYCIVE THERAPEUTICS INC | $4.6M | 1.49% | 796,558 | Common | SHARED |
| 28658R106 | CLYM | CLIMB BIO INC | $3.9M | 1.27% | 979,534 | Common | SHARED |
| 799566104 | SANA | SANA BIOTECHNOLOGY INC | $2.8M | 0.92% | 700,000 | Common | SHARED |
| N69605108 | PHVS | PHARVARIS N V | $2.3M | 0.75% | 82,800 | Common | SHARED |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $2.3M | 0.73% | 124,666 | Common | SHARED |
| 76200L309 | RZLT | REZOLUTE INC | $2.2M | 0.73% | 951,809 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.